摘要
目的探讨早期应用依达拉奉对急性重型脑损伤患者血清C反应蛋白浓度的影响。方法选择本院2011年5月～2013年5月神经外科收治的符合急性重症脑损伤诊断标准(GCS评分为6～8分)患者67例,随机分成治疗组(39例)和对照组(28例),治疗组均于受伤24h内予应用依达拉奉,对照组予一般常规治疗,对比分析治疗组与对照组间的差异。结果治疗组CRP浓度、GCS值在12h、24h、1周、2周、1个月后均比对照组低(P<0.05);治疗组患者在每个时期对应的GCS值表明其随着体内CRP浓度降低、GCS评分越高,即治疗效果越好(R=-0.9869,P<0.01);治疗组3个月预后良好率高于对照组(x2=4.0376,P<0.05);治疗组GOS预后评分显著高于对照组(t=3.9504,P<0.01)。结论早期应用依达拉奉治疗可以降低急性重型脑损伤患者血清C反应蛋白浓度。
Objective To explore the effect of early application of edaravone on levels of serum CRP in treatment of patients with acute severe brain injury. Methods 67 patients who meet the standard of craniocerebral injury（GCS score 6-8）in neurosurgery department of our hospital from May 2011 to May 2013,were randomly divided into treatment group （n=39） and control group （n=28） . The treatment group was given edaravone within injured 24 h,and the control group was given conventional treatment,and the effect was compared between the two groups. Results The CRP levels and GCS value were lower than those in control group after 12 h,24 h,1 week,2 weeks,1 month（P 〈 0.05）. The lower CRP concentration in vivo,the GCS score was higher,the treatment effect was better（R=-0.9869,P 〈 0.01）;the good prognosis rate in treatment group was higher than that in control group after 3 months（χ^2=4.0376,P 〈 0.05）;the GOS score in treatment group was significantly higher than that in control group（t=3.9504,P 〈 0.01）. Conclusion Early application of edaravone can reduce the serum c-reactive protein concentrations of patients with acute severe brain injury.
出处
《中国医药科学》
2013年第14期63-64,共2页
China Medicine And Pharmacy
